AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05520151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORAL IMPACT treatment
Description: the group of patients will be received a 7-days course of ORAL IMPACT
Study NCT05520151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: no intervention
Study NCT05340894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCKENZIE exercises
Description: McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
Study NCT05340894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WILLIAM'S exercises
Description: William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
Study NCT05353400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early urinary catheter removal
Description: Early catheter removal
Study NCT05353400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter removal on POD 3
Description: Catheter removal on POD 3
Study NCT04335942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alert AFNOR 3.6.
Description: This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
Study NCT04335942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alertes  AFNOR 3.6  et alertes  Guidelines .
Description: By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
Study NCT05345535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trampoline exercise
Description: 45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
Study NCT05345535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: 45 minutes of moderate tempo walking
Study NCT04957550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 tablets、Placebo
Description: SHR0302 tablets dose 1 for 48 weeks
Study NCT04957550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 tablets、Placebo
Description: SHR0302 tablets dose 2 for 48 weeks
Study NCT04957550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
Study NCT05223660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose KT07
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12
Study NCT05223660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose KT07
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12
Study NCT05223660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo
Description: A single dose of 4 capsules, followed by multiple doses on Days 8-12
Study NCT05223660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High dose Placebo
Description: A single dose of 6 capsules, followed by multiple doses on Days 8-12
Study NCT05998083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations.
Study NCT05998083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group continued only the individual support education program.
Study NCT05875051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high intensity training
Description: The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
Study NCT05875051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short moderate intensity training
Description: The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.
Study NCT05916781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.
Study NCT05392504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: The core stability training consist of three phases
Study NCT05392504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scroth's Program
Description: The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
Study NCT05544188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Differential diagnostic
Description: Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
Study NCT05544188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Differential diagnostic
Description: Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
Study NCT05365555 — intervention group
Intervention type: PROCEDURE
Intervention: Fascia Iliaca Compartment Block
Description: Blind technique.
Study NCT05365555 — intervention group
Intervention type: PROCEDURE
Intervention: Femoral Nerve Block
Description: Ultrasound guided.
Study NCT05365555 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Description: Ropivacaine dosed according to local guidelines.
Study NCT05080049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.
Study NCT05080049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.
Study NCT05627544 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthesia management/Hip replacement surgery
Description: The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
Study NCT05627544 — intervention group
Intervention type: PROCEDURE
Intervention: Demographic data
Description: The effect of demographic data on blood transfusion practices in hip replacement surgeries
Study NCT05627544 — intervention group
Intervention type: PROCEDURE
Intervention: Chronic diseases
Description: The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
Study NCT05627544 — intervention group
Intervention type: PROCEDURE
Intervention: Postoperative complication
Description: The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
Study NCT06378671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General treatment
Description: routine bronchoscopy examination, lavage, and mucosal biopsy
Study NCT06378671 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General treatment
Description: routine bronchoscopy examination, lavage, and mucosal biopsy
Study NCT06378671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy Treatment
Description: local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
Study NCT04860271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Acupuncture
Description: Manual acupuncture treatment using different types of needle
Study NCT05561361 — intervention group
Intervention type: PROCEDURE
Intervention: Super selective adrenal artery embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
Study NCT05561361 — intervention group
Intervention type: DRUG
Intervention: Spironolactone
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Study NCT06341530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib combined with penpulimab
Description: single arm
Study NCT05167682 — intervention group
Intervention type: OTHER
Intervention: Prehabilitation program
Description: Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
Study NCT06241807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Chemotherapy
Description: Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
Study NCT04623372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
Study NCT04623372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: directed wound healing
Description: application of a dry dressing without any prior suture after the skin biopsy.
Study NCT05097144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (fanfilcon A)
Description: Daily wear for one month
Study NCT05097144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (asmofilcon A)
Description: Daily wear for one month
Study NCT06148987 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
Study NCT04778982 — intervention group
Intervention type: DRUG
Intervention: KN026 combined with Palbociclib and Fulvestrant
Description: HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
Study NCT05045898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plantar massage
Description: The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
Study NCT05045898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured insoles
Description: Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks.
Study NCT04677673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
Study NCT04677673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curative gastrectomy
Description: Radical gastrectomy with D2 lymph node dissection
Study NCT05026281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantra analyzer
Description: one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
Study NCT05453032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn
Description: A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
Study NCT04712396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Subects will be administered single doses of capiversatib on Day 1 and Day 6.
Study NCT04712396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
Study NCT06426251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
Study NCT06426251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
Study NCT05275075 — intervention group
Intervention type: OTHER
Intervention: Pancreatic cancer microRNA and messenger RNA expression.
Description: Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
Study NCT05681000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule
Description: At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively.
Study NCT05410613 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: electromagnetic field and a plantar resistance exercise
Description: Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening).
Study NCT05410613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
Study NCT05410613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: standard general advice according to hospital protocol
Study NCT05326490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-201
Description: PB-201: 100 mg each time, orally in the morning and evening respectively
Study NCT05326490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-201 matched placebo
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively